ACE and COVID-19: Among 77,221 UK Biobank participants (53.5% women), the use of angiotensin-converting enzyme inhibitors induced a potential mortality risk for male COVID-19 patients (OR 1.15, 95% CI 1.01–1.32), but calcium channel blockers exhibited a protective activity (OR 0.87, 95% CI 0.79–0.96).